Home / Stocks / KRYS

Krystal Biotech (KRYS, Biotech) Stock Valuation & Fair Value Mixed on our tests

Krystal Biotech (KRYS, Biotech) trades at a current P/E of 44.7, about 67% below its historical normal valuation, with a forward growth estimate of 30.2% and a PEG of 1.48. Analysts' one-year estimates have been hit 38% of the time. Priced at its historical normal P/E of 135.5 on the same blended earnings, the 2026-10-09 close of $331.61 corresponds to about $1,000 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-10-12
Current P/E
44.7
Normal P/E
135.5
PEG
1.48
Fwd growth
30.2%
Div yield
0.0%
RSI (14)
46.4
Neutral
Technical context
  • Price $332.07 at the 2026-10-12 close, 0.8% below the 20-day average ($334.78) and 2.2% below the 50-day ($339.52).
  • RSI (14) at 46.4.
  • 52-week range $184.74 to $378.15: the price is 12.2% below the high and 79.7% above the low.

The Street vs SeerForecast

Wall Street's mean price target for KRYS is $392.11 across 9 analysts, 18.1% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from poor on forward returns (2026-06-14) to mixed on our tests (2026-10-12). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Current P/E and rating by weekCurrent P/E moved from 36.9 to 44.7 between 2026-06-12 and 2026-10-09, against a normal P/E of 135.5, with 5 rating changes over 37 recorded weeks.2026-06-12: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-06-142026-06-16: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-06-162026-06-18: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-06-212026-07-02: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-07-022026-07-06: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-07-062026-07-09: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-07-092026-07-10: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-07-122026-07-13: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-07-132026-07-14: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-07-142026-07-20: P/E 36.9, Poor on forward returns, recalculated for the week of 2026-07-202026-07-22: P/E 47.4, Mixed on our tests, recalculated for the week of 2026-07-222026-07-24: P/E 47.4, Mixed on our tests, recalculated for the week of 2026-07-252026-07-27: P/E 47.4, Mixed on our tests, recalculated for the week of 2026-07-272026-07-31: P/E 47.4, Mixed on our tests, recalculated for the week of 2026-07-312026-07-31: P/E 47.6, Mixed on our tests, recorded live 2026-08-032026-08-07: P/E 47.6, Mixed on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 45.5, Weak on forward returns, recorded live 2026-08-102026-08-14: P/E 45.5, Weak on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 45.7, Favorable on our tests, recorded live 2026-08-172026-08-21: P/E 45.7, Favorable on our tests, recalculated for the week of 2026-08-212026-08-21: P/E 47.6, Favorable on our tests, recorded live 2026-08-242026-08-27: P/E 47.6, Favorable on our tests, recalculated for the week of 2026-08-272026-08-28: P/E 47.6, Favorable on our tests, recalculated for the week of 2026-08-282026-08-28: P/E 47.6, Favorable on our tests, recalculated for the week of 2026-08-302026-08-28: P/E 48.2, Favorable on our tests, recorded live 2026-08-312026-09-04: P/E 48.2, Favorable on our tests, recalculated for the week of 2026-09-052026-09-04: P/E 48.6, Favorable on our tests, recorded live 2026-09-072026-09-11: P/E 48.6, Favorable on our tests, recalculated for the week of 2026-09-122026-09-11: P/E 47.0, Favorable on our tests, recorded live 2026-09-142026-09-18: P/E 47.0, Favorable on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 45.5, Strong on our tests, recorded live 2026-09-212026-09-25: P/E 45.5, Strong on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 46.6, Mixed on our tests, recorded live 2026-09-282026-10-02: P/E 46.6, Mixed on our tests, recalculated for the week of 2026-10-032026-10-02: P/E 43.4, Mixed on our tests, recorded live 2026-10-052026-10-09: P/E 43.4, Mixed on our tests, recalculated for the week of 2026-10-102026-10-09: P/E 44.7, Mixed on our tests, recorded live 2026-10-1250.075.0100.0125.0Jun 12Jul 12Aug 11Sep 9Oct 9Normal P/E 135.5
Strong on our testsFavorable on our testsMixed on our testsWeak on forward returnsPoor on forward returnsLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-06-14P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-22P/E 47.4-65%Mixed on our tests (recalculated)
2026-08-10P/E 45.5-66%Weak on forward returns
2026-08-17P/E 45.7-66%Favorable on our tests
2026-09-07P/E 48.6-64%Favorable on our tests
2026-09-21P/E 45.5-66%Strong on our tests
2026-09-28P/E 46.6-66%Mixed on our tests (across a rating rules change)
2026-10-12P/E 44.7-67%Mixed on our tests ← now
Show all 37 weeks
WeekCurrent P/EPremium to normal P/ERating
2026-06-14P/E 36.9-73%Poor on forward returns (recalculated)
2026-06-16P/E 36.9-73%Poor on forward returns (recalculated)
2026-06-21P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-02P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-06P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-09P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-12P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-13P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-14P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-20P/E 36.9-73%Poor on forward returns (recalculated)
2026-07-22P/E 47.4-65%Mixed on our tests (recalculated)
2026-07-25P/E 47.4-65%Mixed on our tests (recalculated)
2026-07-27P/E 47.4-65%Mixed on our tests (recalculated)
2026-07-31P/E 47.4-65%Mixed on our tests (recalculated)
2026-08-03P/E 47.6-65%Mixed on our tests
2026-08-07P/E 47.6-65%Mixed on our tests (recalculated)
2026-08-10P/E 45.5-66%Weak on forward returns
2026-08-14P/E 45.5-66%Weak on forward returns (recalculated)
2026-08-17P/E 45.7-66%Favorable on our tests
2026-08-21P/E 45.7-66%Favorable on our tests (recalculated)
2026-08-24P/E 47.6-65%Favorable on our tests
2026-08-27P/E 47.6-65%Favorable on our tests (recalculated)
2026-08-28P/E 47.6-65%Favorable on our tests (recalculated)
2026-08-30P/E 47.6-65%Favorable on our tests (recalculated)
2026-08-31P/E 48.2-64%Favorable on our tests
2026-09-05P/E 48.2-64%Favorable on our tests (recalculated)
2026-09-07P/E 48.6-64%Favorable on our tests
2026-09-12P/E 48.6-64%Favorable on our tests (recalculated)
2026-09-14P/E 47.0-65%Favorable on our tests
2026-09-19P/E 47.0-65%Favorable on our tests (recalculated)
2026-09-21P/E 45.5-66%Strong on our tests
2026-09-26P/E 45.5-66%Strong on our tests (recalculated)
2026-09-28P/E 46.6-66%Mixed on our tests (across a rating rules change)
2026-10-03P/E 46.6-66%Mixed on our tests (recalculated)
2026-10-05P/E 43.4-68%Mixed on our tests
2026-10-10P/E 43.4-68%Mixed on our tests (recalculated)
2026-10-12P/E 44.7-67%Mixed on our tests ← now

Frequently asked questions

Is Krystal Biotech stock overvalued?

At a current P/E of 44.7 versus its historical normal P/E of 135.5, Krystal Biotech trades about 67% below its typical valuation, with a PEG of 1.48 on 30.2% forward growth. tickerseer currently rates it mixed on our tests.

What is Krystal Biotech's fair value and PEG?

Krystal Biotech trades at a current P/E of 44.7 against a historical normal P/E of 135.5, a PEG of 1.48, and a forward growth estimate of 30.2%. Priced at its historical normal P/E of 135.5 on the same blended earnings, the 2026-10-09 close of $331.61 corresponds to about $1,000 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Krystal Biotech changed?

tickerseer's rating moved from poor on forward returns (2026-06-14) to mixed on our tests (2026-10-12). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

What is the analyst price target for Krystal Biotech?

The mean Wall Street price target for Krystal Biotech is $392.11 across 9 analysts, 18.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track KRYS free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.